NASDAQ:GMTX

Gemini Therapeutics Competitors

$11.24
+0.23 (+2.09 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.72
Now: $11.24
$11.83
50-Day Range
$11.01
MA: $14.85
$18.00
52-Week Range
$10.57
Now: $11.24
$19.08
Volume204,493 shs
Average Volume289,509 shs
Market Capitalization$483.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Gemini Therapeutics (NASDAQ:GMTX) Vs. IBRX, IMCR, BCAB, CGEM, SBTX, and KNTE

Should you be buying GMTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Gemini Therapeutics, including ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), Cullinan Oncology (CGEM), Silverback Therapeutics (SBTX), and Kinnate Biopharma (KNTE).

Gemini Therapeutics (NASDAQ:GMTX) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and ImmunityBio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
ImmunityBio00103.00

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 43.84%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than ImmunityBio.

Earnings and Valuation

This table compares Gemini Therapeutics and ImmunityBio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Gemini Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

Gemini Therapeutics beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Immunocore, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
Immunocore01202.67

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 42.05%. Given Gemini Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Immunocore.

Earnings and Valuation

This table compares Gemini Therapeutics and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Profitability

This table compares Gemini Therapeutics and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
ImmunocoreN/AN/AN/A

Summary

Gemini Therapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and BioAtla, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
BioAtla00403.00

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. BioAtla has a consensus target price of $58.00, indicating a potential upside of 21.49%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than BioAtla.

Earnings and Valuation

This table compares Gemini Therapeutics and BioAtla's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Gemini Therapeutics and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

Gemini Therapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Cullinan Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
Cullinan Oncology01302.75

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Cullinan Oncology has a consensus target price of $48.25, indicating a potential upside of 37.07%. Given Gemini Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Cullinan Oncology.

Earnings and Valuation

This table compares Gemini Therapeutics and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Gemini Therapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Gemini Therapeutics beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Earnings and Valuation

This table compares Gemini Therapeutics and Silverback Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gemini Therapeutics and Silverback Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
Silverback Therapeutics00403.00

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Silverback Therapeutics has a consensus target price of $50.25, indicating a potential upside of 33.50%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Silverback Therapeutics.

Profitability

This table compares Gemini Therapeutics and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Summary

Gemini Therapeutics beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.

Gemini Therapeutics (NASDAQ:GMTX) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Gemini Therapeutics and Kinnate Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Gemini Therapeutics and Kinnate Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gemini Therapeutics00403.00
Kinnate Biopharma00403.00

Gemini Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 95.73%. Kinnate Biopharma has a consensus target price of $52.00, indicating a potential upside of 75.44%. Given Gemini Therapeutics' higher possible upside, equities research analysts clearly believe Gemini Therapeutics is more favorable than Kinnate Biopharma.

Profitability

This table compares Gemini Therapeutics and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gemini TherapeuticsN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Summary

Gemini Therapeutics beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.


Gemini Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IBRX
ImmunityBio
1.7$17.38+0.7%$1.90 billionN/A0.00Gap Up
Immunocore logo
IMCR
Immunocore
1.3$38.25+3.0%$1.65 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$47.74+0.4%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.20+2.0%$1.53 billionN/A0.00Gap Down
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$37.64+3.5%$1.31 billionN/A0.00Analyst Report
Gap Down
KNTE
Kinnate Biopharma
1.7$29.64+5.2%$1.29 billionN/A0.00Increase in Short Interest
Gap Down
EWTX
Cricut
0.3$27.08+3.1%$1.29 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$29.03+6.8%$1.29 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$30.10+4.7%$1.12 billionN/A0.00Gap Down
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.27+0.2%$963.96 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$27.92+0.5%$888.97 millionN/A0.00News Coverage
Gap Down
FDMT
4D Molecular Therapeutics
1.3$33.20+9.3%$886.24 millionN/A0.00Increase in Short Interest
News Coverage
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.90+6.9%$845.76 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$13.07+3.9%$834.94 millionN/A0.00Decrease in Short Interest
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36+8.8%$812.29 millionN/A0.00Analyst Report
Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.29+3.4%$782.36 millionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
FNCH
Finch Therapeutics Group
2.0$15.99+3.1%$753.85 millionN/A0.00Analyst Report
Analyst Revision
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.15+3.6%$615.42 millionN/A0.00
SGTX
Sigilon Therapeutics
1.4$17.04+8.2%$536.64 millionN/A0.00Increase in Short Interest
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.34+0.5%$515.32 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.51+2.1%$461.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.91+1.1%$449.99 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.12+5.8%$431.90 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$18.74+12.1%$426.49 millionN/A0.00News Coverage
Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.07+5.6%$414.84 millionN/A0.00
PRTG
Portage Biotech
0.0$26.99+7.6%$326.12 millionN/A0.00High Trading Volume
News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.34+4.1%$292.09 millionN/A-2.84Gap Down
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.50+16.2%$276.04 millionN/A-2.57Unusual Options Activity
News Coverage
Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.89+8.7%$246.28 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$11.63+7.0%$196.75 millionN/A0.00Analyst Report
Quiet Period Expiration
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.10+3.4%$193.10 millionN/A0.00Increase in Short Interest
Gap Up
GANX
Gain Therapeutics
1.7$14.50+2.8%$164.30 millionN/A0.00Analyst Revision
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55+0.1%$149.71 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.60+4.0%$144.41 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52+18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52+9.5%$123.60 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.87+6.5%$84.17 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$14.76+2.8%$57.68 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24+3.4%$52.67 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.58+1.1%$46.48 millionN/A0.00News Coverage
Gap Down
VIRX
Viracta Therapeutics
1.7$8.00+0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65+0.3%$40.18 millionN/A0.00News Coverage
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20+6.3%$37.69 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.55+2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36+3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26+23.2%$12.65 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.26+0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57+4.7%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00High Trading Volume
Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.